Search research articles
Contact Us
Filters
Showing results (201-210 of 258) with videos related to
Page
of 26
Sort By:
Allergy
|
November 17, 2022
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria
Dorothea Terhorst-Molawi, Tomasz Hawro, Eva Grekowitz, et al.
Acta Dermato-Venereologica
|
January 18, 2019
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)
Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, et al.
Allergy
|
October 24, 2025
On the Kinetics of Human Skin Mast Cell Depletion and Repopulation Following KIT Inhibition
Diego Alvarado, Deena M Maurer, Philip Golden, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 8, 2025
Development and Reliability Assessment of an Artificial Intelligence-Driven Urticaria Support Chatbot, AIDUS
Felix Aulenbacher, Annika Gutsche, Benedict Bihlmaier, et al.
Theranostics
|
April 25, 2017
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin
Martin Metz, Petra Staubach, Andrea Bauer, et al.
The Journal of Allergy and Clinical Immunology
|
February 26, 2026
A Randomized Dose-Finding Study of Anti-KIT Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Martin Metz, Essack Mitha, Jeffrey Leflein, et al.
Nature Medicine
|
July 24, 2007
IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities
Zane Orinska, Marcus Maurer, Farhad Mirghomizadeh, et al.
Clinical and Translational Allergy
|
July 3, 2026
A Real-World Cross-Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified
Annika Gutsche, Thomas Buttgereit, Rüdiger Buchkremer, et al.
The World Allergy Organization Journal
|
November 28, 2022
Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria
Martin Metz, Jonathan A Bernstein, Ana M Giménez-Arnau, et al.
The Journal of Clinical Investigation
|
September 20, 2011
Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice
Mitsuteru Akahoshi, Chang Ho Song, Adrian M Piliponsky, et al.
Page
of 26
Search research articles
Search
Showing results (201-210 of 258) with videos related to
Sort By:
Page
of 26
Allergy
|
November 17, 2022
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria
Dorothea Terhorst-Molawi, Tomasz Hawro, Eva Grekowitz, et al.
Acta Dermato-Venereologica
|
January 18, 2019
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)
Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, et al.
Allergy
|
October 24, 2025
On the Kinetics of Human Skin Mast Cell Depletion and Repopulation Following KIT Inhibition
Diego Alvarado, Deena M Maurer, Philip Golden, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 8, 2025
Development and Reliability Assessment of an Artificial Intelligence-Driven Urticaria Support Chatbot, AIDUS
Felix Aulenbacher, Annika Gutsche, Benedict Bihlmaier, et al.
Theranostics
|
April 25, 2017
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin
Martin Metz, Petra Staubach, Andrea Bauer, et al.
The Journal of Allergy and Clinical Immunology
|
February 26, 2026
A Randomized Dose-Finding Study of Anti-KIT Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Martin Metz, Essack Mitha, Jeffrey Leflein, et al.
Nature Medicine
|
July 24, 2007
IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities
Zane Orinska, Marcus Maurer, Farhad Mirghomizadeh, et al.
Clinical and Translational Allergy
|
July 3, 2026
A Real-World Cross-Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified
Annika Gutsche, Thomas Buttgereit, Rüdiger Buchkremer, et al.
The World Allergy Organization Journal
|
November 28, 2022
Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria
Martin Metz, Jonathan A Bernstein, Ana M Giménez-Arnau, et al.
The Journal of Clinical Investigation
|
September 20, 2011
Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice
Mitsuteru Akahoshi, Chang Ho Song, Adrian M Piliponsky, et al.
Page
of 26